Janus Henderson Group PLC Chinook Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $1,119 - $2,314	-60 Reduced 0.3%	19,736 $758,000
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $211,166 - $262,854	9,808 Added 98.2%	19,796 $458,000
Q4 2022 Feb 14, 2023	BUY	$18.63 - $27.35 $186,076 - $273,171	9,988 New	9,988 $261,000
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $125,937 - $188,056	10,003 New	10,003 $175,000
Q2 2021 Aug 16, 2021	SELL	$13.6 - $18.98 $2.36 Million - $3.29 Million	-173,551 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $2.07 Million - $3.63 Million	173,551 New	173,551 $2.75 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.